Lumibird Group, the diverse European laser technology developer, has announced the acquisition by its subsidiary Quantel Medical of the Slovenian firm Optotek Medical d.o.o., which specializes in optical and laser solutions for medical applications.

Lumibird said, “This acquisition marks the culmination of the longstanding collaboration established between the two companies through OEM contracts to develop and supply devices for Quantel Medical’s range of anterior chamber lasers.”

The company added that the deal – financial details of which were not disclosed – will enable Quantel Medical “to further strengthen its research and development expertise for medical lasers and its industrial integration with an additional ISO 13485 certified production unit based in Ljubljana, Slovenia.”

Optotek Medical’s revenues amounted to €6.6 million in 2018: nearly two thirds of this were recorded in business with Quantel Medical, with the balance generated by a range of ophthalmic lasers sold in around 30 countries. Optotek has built up advanced optics and micro-mechanical expertise.

'Treatment of secondary cataracts and glaucoma

Jean Marc Gendre, Quantel Medical’s manager, commented, “The co-developments by Quantel Medical and Optotek Medical over nearly the past 20 years have made it possible to bring innovative solutions to the market for the treatment of secondary cataracts and glaucoma. This acquisition represents the logical culmination of our longstanding collaboration and the start of a new stage in our development.”

Marc Le Flohic, Lumibird’s Chairman and CEO, added, “This acquisition is in line with the Lumibird Group’s rationale to offer its clients new strong value-added products and ensure full control over their development and production chain.

”We are not only strengthening our range of laser treatment products for ophthalmology, but we are also expanding our selection of OEM solutions for buoyant markets such as dermatology or ENT surgery with articulated arms.”

The industrial, technological and commercial synergies between the two companies will make it possible to further strengthen the competitiveness of the ophthalmic lasers already released, while accelerating the development of new products.

The Lumibird Group, established in 2017, consists of two divisions: the Laser division, incorporating Keopsys, Quantel and SensUp, offering lasers for industrial, defense, scientific and medical applications – products are based on three key technologies: fiber lasers, solid-state lasers and laser diodes; and the Quantel Medical division, which mainly offers diagnostic and treatment equipment for ophthalmology based on lasers and ultrasonic sensors.